Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

FOSAPREPITANT DIMEGLUMINE vs FOSTAMATINIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

FOSAPREPITANT DIMEGLUMINE vs FOSTAMATINIB: Safety Overview

Metric	FOSAPREPITANT DIMEGLUMINE	FOSTAMATINIB
Total FAERS Reports	888	6,394
Deaths Reported	118	453
Death Rate	13.3%	7.1%
Hospitalizations	364	1,493
Average Patient Age	57.0 yrs	64.7 yrs
% Female Patients	50.1%	60.8%
FDA Approval Date	Aug 20, 2020	Apr 17, 2018
Manufacturer	Dr. Reddy's Laboratories Inc.,	Rigel Pharmaceuticals, Inc.
Route	INTRAVENOUS	ORAL
Marketing Status	Discontinued	Prescription